Teva Pharmaceuticals
TEVA
TEVA
445 hedge funds and large institutions have $6.16B invested in Teva Pharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 67 funds opening new positions, 132 increasing their positions, 143 reducing their positions, and 47 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
more funds holding in top 10
Funds holding in top 10: →
more ownership
Funds ownership: →
3% more funds holding
Funds holding: 433 → 445 (+12)
5% less call options, than puts
Call options by funds: $165M | Put options by funds: $174M
8% less repeat investments, than reductions
Existing positions increased: 132 | Existing positions reduced: 143
Holders
445
Holding in Top 10
20
Calls
$165M
Puts
$174M
Top Buyers
1 | +$111M | |
2 | +$89.5M | |
3 | +$54.4M | |
4 |
GAM
Goldentree Asset Management
New York
|
+$40.5M |
5 |
MRCP
Maple Rock Capital Partners
Toronto,
Ontario, Canada
|
+$27.1M |
Top Sellers
1 | -$104M | |
2 | -$47.2M | |
3 | -$20.6M | |
4 |
Jane Street
New York
|
-$15.2M |
5 |
RCM
Rokos Capital Management
London,
United Kingdom
|
-$13.9M |